2017 年 5 月(No71）の記事要旨と参考文献
参考文献はアクセスが容易になるように、できる限りネットへのリンクをつけたものにしています（特に PubMed アブストラクトへリンクできるよう）
P50

1Editorialp51

Free

http://www.npojip.org/chk_tip/71-Editorial.pdf

総説

p52-53

参考文献
1) マンモグラフィーによる乳がんスクリーニング(Part 1). Prescr Int. 2015, 24(158): 72-73. (抄訳: 薬のチェックTIP. 2016, 16(63): 21-23.)
2) 同(Part2,3): 同上2015, 24(159):99-101,24(162):186-190(抄訳: 同,2016, 16(66):92-94)
3) 薬のチェックTIP 編集委員会、マンモグラフィー検診は受けなくてよい. 薬のチェックTIP.
2016: 16(67): 118
4) Donker M, Litière S, Werutsky G, Julien JP et al. Breast-conserving treatment with or without
radiotherapy in ductal carcinoma In Situ: 15-year recurrence rates and outcome after a recurrence,from the EORTC 10853 randomized phase III trial. J Clin Oncol. 2013 Nov 10;31(32):4054-9.
https://www.ncbi.nlm.nih.gov/pubmed/24043739
5) Wapnir IL, Dignam JJ, Fisher B et al. Long-term outcomes of invasive ipsilateral breast tumor
recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl2Cancer Inst. 2011 Mar 16;103(6):478-88.
https://www.ncbi.nlm.nih.gov/pubmed/21398619
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3107729/
6) Fisher B, Costantino JP, Wickerham DL et al Tamoxifen for prevention of breast cancer: report ofthe National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998 Sep
16;90(18):1371-88. https://www.ncbi.nlm.nih.gov/pubmed/9747868
7) Cuzick J, Powles T, Ve ronesi U et al. Overview of the main outcomes in breast-cancer prevention
trials. Lancet. 2003 Jan 25;361(9354):296-300. https://www.ncbi.nlm.nih.gov/pubmed/12559863
8) Cuzick J, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A, Forbes JF; IBIS-I Investigators.
Tamoxifen for prevention of breast cancer extended long-term follow-up of the IBIS-I breast cancer
prevention trial. Lancet Oncol. 2015 Jan;16(1):67-75.
https://www.ncbi.nlm.nih.gov/pubmed/25497694

P54-57

Web 資料あり
参考文献
1. 薬害オンブズパースン会議、WHO ワクチン安全性諮問委員会（GACVS）の HPV ワクチンに関する声明（2015 年 12 月 17 日付）に対する反論、
http://www.yakugai.gr.jp/topics/file/20161102_refutation_of_gacvs_statement_on_safety_of_hpv_vaccines_20151217_japanese.pdf
2. 1. Gøtzsche PC, Jefferson T, Auken M, Brinth L. Complaint to the European ombudsman overmaladministration at the European Medicines Agency (EMA) in relation to the safety of the HPV vaccines.
http://nordic.cochrane.org/sites/nordic.cochrane.org/files/public/uploads/ResearchHighlights/Complaint-toombudsman-over-EMA.pdf [accessed 27.01.17]
3. Quinn M, Babb P, Jones J, Allen E.Effect of screening on incidence of and mortality from cancer ofcervix in England: evaluation based on routinely collected statistics. BMJ. 1999 Apr 3;318(7188):904-8.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC27810/
4. Shastri SS, Mittra I, Mishra GA, Gupta S, Dikshit R, Singh S, Badwe RA. Effect of VIA screening byprimary health workers: randomized controlled study in Mumbai, India.
J Natl Cancer Inst. 2014 Mar;106(3):dju009. doi: 10.1093/jnci/dju0
https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/dju009
5. HPV screening for cervical cancer in rural India.
3

Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, Hingmire S, Malvi SG,Thorat R, Kothari A, Chinoy R, Kelkar R, Kane S, Desai S, Keskar VR, Rajeshwarkar R, Panse N,Dinshaw KA. N Engl J Med. 2009 Apr 2;360(14):1385-94. doi: 10.1056/NEJMoa0808516.
http://www.nejm.org/doi/pdf/10.1056/NEJMoa0808516
6. Sankaranarayanan R, Esmy PO, Rajkumar R, Muwonge R, Swaminathan R, Shanthakumari S, Fayette
JM, Cherian J.Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu,India: a cluster-randomised trial.Lancet. 2007 Aug 4;370(9585):398-406.
https://www.ncbi.nlm.nih.gov/pubmed/17679017
7. 人口動態統計
http://www.e-stat.go.jp/SG1/estat/OtherList.do?bid=000001041646&cycode=7
8. 浜六郎ら、子宮頸がんの疫学と HPV ワクチン、The Informed Prescriber 2013:28(2):27-31. http://www.npojip.org/contents/link/tip-free/2013/2013_04.pdf
9. Kripke DF, Garfinkel L, Wingard DL et al. Mortality associated with sleep duration and insomnia. ArchGen Psychiatry. 2002 Feb;59(2):131-6. https://www.ncbi.nlm.nih.gov/pubmed/11825133
10. Klerman EB, Dijk DJ. Age-related reduction in the maximal capacity for sleep--implications forinsomnia. Curr Biol. 2008 Aug 5;18(15):1118-23. file:///C:/Users/Roku/Downloads/srep35812.pdf
11. Kitamura S, Katayose Y, Nakazaki K et al. Estimating individual optimal sleep duration andpotential sleep debt. Sci Rep. 2016 Oct 24;6:35812. http://www.nature.com/articles/srep35812
12.浜六郎、「薬のやめ方」事典、三五館、2017
p57

p.58-59

4参考文献1) Laing KJ et al. Zoster vaccination increases the breadth of CD4+ T cells responsive to Varicellazoster virus. J Infect Dis 2015;212:1022-31.
https://www.ncbi.nlm.nih.gov/pubmed/25784732
2) Gagliardi AM et al. Vaccines for preventing herpes zoster in older adults. Cochrane Database
Syst Rev. 2016 Mar 3;3:CD008858.
https://www.ncbi.nlm.nih.gov/pubmed/23076951
3) Tseng HF et al. Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster
disease. JAMA 2011;305:160-6.
https://www.ncbi.nlm.nih.gov/pubmed/21224457
4) Oxman MN et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
N Engl J Med 2005;352:2271-84.
5) Schmader KE et al. Persistence of the efficacy of zoster vaccine in the shingles prevention
study and the short-term persistence substudy. Clin Infect Dis 2012;55:1320-8.
https://www.ncbi.nlm.nih.gov/pubmed/22828595
6) Morrison VA et al. Long-term persistence of zoster vaccine efficacy. Clin Infect Dis
2015;60:900-9. https://www.ncbi.nlm.nih.gov/pubmed/25416754
7) Lai YC, Yew YW. Severe autoimmune adverse events post herpes zoster vaccine: acase-control study of adverse events in a national database. J Drugs Dermatol 2015;14:681–4.
https://www.ncbi.nlm.nih.gov/pubmed/26151783
8) Tseng HF et al. Herpes zoster vaccine and the incidence of recurrent herpes zoster in an
immunocompetent elderly population. J Infect Dis 2012;206:190-6
https://www.ncbi.nlm.nih.gov/pubmed/22669900 .
9) Le P, Rothberg MB. Cost-effectiveness of herpes zoster vaccine for persons aged 50 years. Ann
Intern Med 2015;163:489-97. https://www.ncbi.nlm.nih.gov/pubmed/26344036
10) Cunningham AL et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age
or older. N Engl J Med 2016;375:1019-32.
https://www.ncbi.nlm.nih.gov/pubmed/27626517
11) 浜六郎、アジュバントって何？ 薬のチェックは命のチェック 2014：14(53)：47-67.
http://www.npojip.org/contents/book/mag053.html
http://www.npojip.org/sokuho/140128.html (Free)

5

P62

以下記事を参考文献
参考文献

1) Prescrire Editorial Staff “Irritable bowel syndrome. A mild disorder; purely symptomatictreatment”Prescrire Int 2009; 18 (100): 75-79.
2) EMA - CHMP “Assessment report for linaclotide. EMEA/H/C/2490”20 September 2012: 3) US
FDA - CDER “Application Number: 202811Orig1s000 - Medical Review(s)”16 August 2012:4) Rao S et al. “A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period
to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation”Am J
Gastroenterol 2012; 107 (11): 1714-1724.
5) Chey WD et al. “Linaclotide for irritable bowel syndrome with constipation: a 26-week,randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety”Am J
Gastroenterol 2012; 107 (11): 1702-1712.
6) European Commission “SPC-Constella”20 February 2014: 11 pages.
7) Lembo AJ et al. “Two randomized trials of linaclotide for chronic constipation”N Eng J Med 2011;
365 (6): 527-536.
8) Lin JE, Valentino M, Marszalowicz G et al. Bacterial heat-stable enterotoxins: translation ofpathogenic peptides into novel targeted diagnostics and therapeutics. Toxins (Basel). 2010
Aug;2(8):2028-54. https://www.ncbi.nlm.nih.gov/pubmed/22069671
9)Ford AC, Suares NC.Effect of laxatives and pharmacological therapies in chronic idiopathic
constipation: systematic review and meta-analysis. Gut 2011;60(2):209-218.
10) 薬のチェックTIP 編集委員会、ルビプロストン(商品名:アミティーザ):使用不可、害が大きすぎる、薬のチェックTIP、2015:15(59): 55-57 http://www.npojip.org/chk_tip.html#No59

P63

Prescrire 評価

薬のチェック TIP 評価

6P65

参考文献
1) Health Canada “Summary safety review Over the counter products containing
pseudoephedrine-Assessing the potential risk of inflammation and injury of the large intestine due toinsufficient blood supply(ischemic coliris)”24 February 2016; 2pages.
2) Prescrire Redaction “16-1-2 Patients sous vasoconstricteur decongestionnant”Rev Prescrire
2016;36(386 suppl Interactions medicamenteuses).
3) Sherid M et al. “Pseudoephedrine-induced ischemic colitis :case report and literature review”J
Digest Dis 2014; 15: 276-280.
4) Prescrire Editorial Staff “Ischaemic colitis on pseudoephedrine” Prescrire Int 2001; 10(54):117.

P66

以下本文を7

参考文献
1) ANSM “Reunion du comite technique de pharmacovigilance, compte rendu de la seance du 15
decembre 2015. Suivi batuibak de ogarnacivugukabce des soecuakutes a base de sofosbuvir etdaclatasvir Sovaldi Harvoni Daklinza“9 January 2016; 18-21.
2) Renard S et al. “Severe pulmonary arterial hypertension in patients treated for hepatitis C with
sofosbuvir“Chest 2016; 149(3): 69-73.
3) Savale L et al. “Direct-acting antiviral medications for hepatitis C virus infection and pulmonary
arterial hypertension”Chest 2016; 150(1):256-258.
4) Prescrire Redaction “Notice Harvoni (sofosbuvir+ledipasvir):quasiabsence d’information surles
effects indesirables“Rev prescrire 2016; 36(389):223.
5) European Commission “SPC-Harvoni“22 July 2016; 53pages.
6) European Commission “SPC-Sovaldi”28 January 2016; 44pages.

P66

参考文献
1) Health Canada “Summary Safety Review AVASTIN(bevacizumab)-Assessing the Potential Risk ofIrreversible Vocal Cord Damage(vocal cord necrosis)”30 November 2015 www.sc-hc.gc.caaccessed
13 February 2016:2page2) Kountourakis P et al.”Voice disorders induced by bevacizumab administration in an ovarian cancer
patient: an underestimated and rare toxicity”Hematol Oncol Stem Cell Ther 2014;7(3):123-124.
3) Saavedra E et al. “Dysphonia Induced by anti-angiogenic compounds” Investigational New Drugs
2014;32(4):774-782.

P67

参考文献
1) FDA ”Drug Safety Communication: FDA warns about several safety issues with opioid painmedicines”22 March 2016: 11pages.
2) Debono M et al.”Tramadol-induced adrenalinsufficiency”Eur J Clin Pharmacol 2011:67:865-867.
3) “Opioid analgesics”. In:”Martindale The Complete Drug Reference”The Pharmaceutical press,London. www.medicinescomplete.com accessed 17 Aprill 2016:21pages.
4) Prescrire Editorial Staff “Opioid and hypogonadism”Prescrire Int. 2012;21(126):98-99.
5) Lee AS and Twigg SM “Opioid-induced secondary adrenal insufficiency presenting ashypercalcaemia”Endocrinol Diabetes Metab 2015:5pages.
6) “Policola C et al. “Adrenal insufficiency in acute oral opiate therapy” Endocrinol Diabetes Metab2014:3pages.
8

P68-69

P70

連載：医薬品危険性情報

あれこれ

日本の国立医薬品食品衛生研究所が発行している「医薬品安全性情報（海外規制機関）」から薬剤の害反応を紹介し、本誌編集委員がコメントする。
【WHO】デノスマブ:血管炎【カナダHealth Canada】インターフェロンß製剤:肺動脈性肺高血圧【英MHRA】C型肝炎治療用の直接作用型抗ウイルス剤:ビタミンK拮抗剤との相互作用によりPT-INR変動が生じるリスク
P71「つくられた恐怖の点滴殺人事件 守大助さんは無実だ」

P72

編集後記

9